117 related articles for article (PubMed ID: 8292816)
21. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
Adams DJ; Knick VC
Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
26. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin.
Levêque D; Jehl F; Quoix E; Breillout F
J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784
[TBL] [Abstract][Full Text] [Related]
29. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.
Hotta K; Sekine I; Tamura T; Sawada M; Watanabe H; Kusaba H; Akiyama Y; Inoue A; Shimoyama T; Nokihara H; Ueda Y; Yamamoto N; Kunitoh H; Ohe Y; Kodama T; Saijo N
Jpn J Clin Oncol; 2001 Dec; 31(12):596-600. PubMed ID: 11902490
[TBL] [Abstract][Full Text] [Related]
31. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
32. In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16).
Roussakis C; Pouchus YF; Gratas C; Riou D; Dimou P; Dabouis G; Merle S; Verbist JF
Anticancer Drug Des; 1993 Apr; 8(2):165-71. PubMed ID: 8388219
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
34. [Vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer previously treated with taxane-based chemotherapy].
Zhang W; Cao JN; Yin JL; Hong XN; Xu LG
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):587-9. PubMed ID: 14690569
[TBL] [Abstract][Full Text] [Related]
35. [Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer].
Uchida J; Satake H; Saito H; Nakano K; Takeda S; Unemi N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1001-8. PubMed ID: 8210249
[TBL] [Abstract][Full Text] [Related]
36. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
38. [Phase II study of combined Vinorelbine (Navelbine) plus cisplatin for advanced non-small cell lung cancer (an interim report)].
Mori K; Kamiyama Y; Kondoh T; Tominaga K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):405-10. PubMed ID: 11915730
[TBL] [Abstract][Full Text] [Related]
39. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer.
Berthaud P; Le Chevalier T; Ruffie P; Baldeyrou P; Arriagada R; Besson F; Tursz T
Eur J Cancer; 1992; 28A(11):1863-5. PubMed ID: 1327022
[TBL] [Abstract][Full Text] [Related]
40. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
